Back

The utility of the HFA-ICOS cardiotoxicity risk assessment tool for HER2-targeted cancer therapies in patients with metastatic breast cancer: from theory to clinical practice.

28 August 2023 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Cardiotoxicity: mechanisms, biomarkers, and treatment Cardio-Oncology ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Daniela Leticia Leocachin Parra

UMAE Hospital de Cardiologia CMN Siglo XXI IMSS, Mexico City (Mexico)

7 More presentations in this session

Presentation thumbnail
The potentially protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients
Doctor S. Maragkoudakis (Chania, GR)
Abstract Slides Video
Presentation thumbnail
SGLT2 i Dapagliflozin reduces NF-kB expression in heart and kydneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways: an hystological study
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
SGLT2i Dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
The use of high sensitivity troponin T as a biomarker of anthracycline cardiotoxicity
Doctor C. Bannister (London, GB)
Abstract Slides Video
Presentation thumbnail
Differences in the prevalence of cardiovascular toxicity in a cohort of female breast cancer patients according to the different cardiotoxicity definitions
Doctor J. Herrera (Cordoba, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiotoxicity: mechanisms, biomarkers, and treatment

The Event

Event poster

ESC Congress 2023

28 August 2023 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Cardiotoxicity risk assessment using HFA-ICOS score: a cross-sectional analysis of patients with breast cancer undergoing chemotherapy or anti-HER2 therapies in a tertiary care center
thumbnail
Congress Presentation
Evaluation of the predictive value of the HFA-ICOS score for cardiotoxicity in breast cancer patients treated with anthracyclines and trastuzumab: a real-world observational study
thumbnail
Congress Presentation
Validation of the HFA-ICOS risk assessment tool with real-world data from a prospective cohort of breast cancer patients in treatment with anthracyclines and trastuzumab

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources